Latest news with #lungcancer
Yahoo
13 hours ago
- Business
- Yahoo
Why Summit Therapeutics Plunged Today
Summit Therapeutics released more data from another HARMONi phase 3 trial. Results were "mixed," which perhaps led to some disappointment in this stock, which had rocketed higher over the past year. Still, all hope is not lost, analysts say. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning. Summit has been a tremendous winner over the past year, as its bispecific antibody lung cancer drug ivonescimab outperformed prior standards of care in phase 3 trials performed in China by Summit's partner Akeso (OTC: AKES.F). While today's results weren't all bad by any means, apparently investors had hoped for more conclusive information about survival rates. With such high expectations, it appears investors are taking profits or de-risking in a big way. Today's release showed results of the fourth phase 3 trial known as "HARMONi," the first to include a significant Western patient population (about a third of participants). Last year's positive results largely came from a China-only study. On the positive side, today's data did show that ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 48%. In addition, the company noted no significant differences between the Asian and Western patient populations. However, the trial didn't show a "statistically significant" benefit in overall survival. Summit has been hoping to apply for FDA approval for ivonescimab in the U.S., but the FDA has told the company it will need to show that statistically significant survival benefit in order to get it. Investors may be getting nervous about that eventual approval. However, analysts don't believe investors should panic. Jefferies biotech analyst Kelly Shi noted the survival endpoint still has a chance of being reached as the data matures further and Western trial patients continue to show survival benefits. So basically, it doesn't appear as though the trial has lasted long enough to reach the statistically significant survival threshold, which doesn't mean that it won't get there. Another analyst was also bullish on the data, despite today's drop. Cantor Fitzgerald biotech analyst Eric Schmidt said, "We think it is fairly clear that this is a drug! ... In each of these four trials, the data posted by ivonescimab appear differentiated from and superior to PD-1 therapy." Therefore, investors may want to take a look at Summit on this drop. While today's data didn't meet the threshold many investors had been hoping for, there is still a chance that it will with more time. Given the success ivonescimab has demonstrated over the past year, it seems likely, though not certain, the drug will eventually be approved. Of course, it's a bit difficult to value a stock like Summit, which has a promising drug candidate but no real current revenues and a market cap that, even down 30% today, is still over $13.5 billion. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group and Summit Therapeutics. The Motley Fool has a disclosure policy. Why Summit Therapeutics Plunged Today was originally published by The Motley Fool
CTV News
19 hours ago
- Health
- CTV News
Wildfire smoke exposure may shorten lung cancer survival
Manitoba RCMP officers assisted with the evacuation of several northern communities in Manitoba including the City of Flin Flon, Pimicikamak Cree Nation, and Mathias Colomb Cree Nation on May 28 and 29, 2025. THE CANADIAN PRESS/HO - Manitoba RCMP Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among non-smokers, but the effect may be mitigated by certain cancer treatments, according to a large California study presented at a major medical meeting on Saturday. Researchers tracked more than 18,000 people with non-small cell lung cancer – the most common kind – between 2017 and 2020. Those living in neighborhoods with the highest levels of wildfire-caused air pollution in the year after their cancer diagnosis were more likely to die from the disease, they found. Patients who inhaled higher levels of tiny particulate matter with a diameter of 2.5 microns or less that can penetrate deeply into the lungs had a 20% greater risk of dying from lung cancer, researchers reported at the American Society of Clinical Oncology meeting in Chicago. People with advanced stage 4 cancer who had never smoked were especially affected, researchers found. Their risk of dying from cancer was 55% higher if they were exposed to high levels of wildfire air pollution. The study used advanced modeling to estimate daily air quality at patients' home addresses, based on data from satellites, weather models, smoke forecasts and air quality monitors. The researchers also found that wildfire smoke exposure did not significantly affect survival of patients with Stage 4 lung cancer with a history of smoking who were treated with an immunotherapy drug. 'This surprising trend suggests that smoke-related changes in the body may interact with certain treatments,' and more study of this phenomenon is warranted, the researchers said. Wildfire smoke is more toxic than normal air pollution. Along with particles of soil and biological materials, it often contains traces of chemicals, metals, plastics and other synthetic materials. 'As wildfires become more frequent and intense in California and other parts of the U.S., we need targeted health strategies to protect cancer patients and others with serious health problems,' said study leader Dr. Surbhi Singhal of UC Davis Comprehensive Cancer Center in Sacramento, California. Reporting by Nancy Lapid; Editing by Bill Berkrot
Reuters
a day ago
- General
- Reuters
Wildfire smoke exposure may shorten lung cancer survival
May 31 (Reuters) - Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among non-smokers, but the effect may be mitigated by certain cancer treatments, according to a large California study presented at a major medical meeting on Saturday. Researchers tracked more than 18,000 people with non-small cell lung cancer – the most common kind – between 2017 and 2020. Those living in neighborhoods with the highest levels of wildfire-caused air pollution in the year after their cancer diagnosis were more likely to die from the disease, they found. Patients who inhaled higher levels of tiny particulate matter with a diameter of 2.5 microns or less that can penetrate deeply into the lungs had a 20% greater risk of dying from lung cancer, researchers reported at the American Society of Clinical Oncology meeting in Chicago. People with advanced stage 4 cancer who had never smoked were especially affected, researchers found. Their risk of dying from cancer was 55% higher if they were exposed to high levels of wildfire air pollution. The study used advanced modeling to estimate daily air quality at patients' home addresses, based on data from satellites, weather models, smoke forecasts and air quality monitors. The researchers also found that wildfire smoke exposure did not significantly affect survival of patients with Stage 4 lung cancer with a history of smoking who were treated with an immunotherapy drug. 'This surprising trend suggests that smoke-related changes in the body may interact with certain treatments,' and more study of this phenomenon is warranted, the researchers said. Wildfire smoke is more toxic than normal air pollution. Along with particles of soil and biological materials, it often contains traces of chemicals, metals, plastics and other synthetic materials. 'As wildfires become more frequent and intense in California and other parts of the U.S., we need targeted health strategies to protect cancer patients and others with serious health problems,' said study leader Dr. Surbhi Singhal of UC Davis Comprehensive Cancer Center in Sacramento, California.
Yahoo
a day ago
- General
- Yahoo
Wildfire smoke exposure may shorten lung cancer survival
By Nancy Lapid (Reuters) -Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among non-smokers, but the effect may be mitigated by certain cancer treatments, according to a large California study presented at a major medical meeting on Saturday. Researchers tracked more than 18,000 people with non-small cell lung cancer – the most common kind – between 2017 and 2020. Those living in neighborhoods with the highest levels of wildfire-caused air pollution in the year after their cancer diagnosis were more likely to die from the disease, they found. Patients who inhaled higher levels of tiny particulate matter with a diameter of 2.5 microns or less that can penetrate deeply into the lungs had a 20% greater risk of dying from lung cancer, researchers reported at the American Society of Clinical Oncology meeting in Chicago. People with advanced stage 4 cancer who had never smoked were especially affected, researchers found. Their risk of dying from cancer was 55% higher if they were exposed to high levels of wildfire air pollution. The study used advanced modeling to estimate daily air quality at patients' home addresses, based on data from satellites, weather models, smoke forecasts and air quality monitors. The researchers also found that wildfire smoke exposure did not significantly affect survival of patients with Stage 4 lung cancer with a history of smoking who were treated with an immunotherapy drug. 'This surprising trend suggests that smoke-related changes in the body may interact with certain treatments,' and more study of this phenomenon is warranted, the researchers said. Wildfire smoke is more toxic than normal air pollution. Along with particles of soil and biological materials, it often contains traces of chemicals, metals, plastics and other synthetic materials. 'As wildfires become more frequent and intense in California and other parts of the U.S., we need targeted health strategies to protect cancer patients and others with serious health problems,' said study leader Dr. Surbhi Singhal of UC Davis Comprehensive Cancer Center in Sacramento, California.
CTV News
2 days ago
- General
- CTV News
‘Never Smoked a day in my life': Albertans taking steps to kick lung cancer stigma
Emi Bossio of Calgary, pictured with her family, was diagnosed with lung cancer in her 40s. Lung cancer is the most common and deadliest cancer but it receives much less funding than others. A group of Albertans is trying to change that. The Give a Breath 5K walk/run aims to kick the stigma of lung cancer, often associated with smoking even though that is not true in many cases. 'Unfortunately, I'm not a rare case, and particularly young women are more and more being diagnosed as never-smokers with lung cancer,' said Emi Bossio. The Calgary mom was in her 40s, never smoked, didn't drink, watched what she ate and exercised when she was diagnosed with lung cancer. Tim Monds of Edmonton has a similar story but was diagnosed in his 50s. 'Never smoked a day in my life. We know that there's many environmental things—radon and other sorts of things—that can cause cancer,' said Monds, who founded Give a Breath. Bossio is hosting Calgary's first walk for the cause in Nose Hill this year—the same day Monds hosts the Edmonton version. Tim Monds of Edmonton, pictured with his family, was diagnosed with lung cancer in his 50s. Tim Monds of Edmonton, pictured with his family, was diagnosed with lung cancer in his 50s. They hope the events will make more people aware because more than 2,000 Albertans each year are diagnosed with lung cancer. 'More people die of lung cancer than breast, prostate and colon cancer put together,' said Monds. 'It's the most common cancer and is the deadliest cancer,' said Dr. Alain Tremblay, pulmonologist and professor and researcher at the University of Calgary's Cumming School of Medicine. Symptoms include a persistent cough, chest pain and shortness of breath. A major advancement is the increased use of screening. 'The idea is to detect the disease early—usually before it can cause any symptoms. That's done with a painless test called a low-dose CT scan that takes about 20 seconds to do,' said Tremblay. Currently, Alberta only offers this screening for people who have smoked, but this group hopes that will change soon. Money raised for the upcoming event will support patients, caregivers and research. 'I'm living proof that research saves lives and extends survival,' said Bossio. 'Thanks to research… seven years of Stage 4 right now,' said Monds. The Give a Breath 5K will take place Saturday, June 7, in Calgary, Edmonton, Vancouver, Toronto and Ottawa. You can follow the links for details on: The event. What it supports. And Alberta lung cancer screening.
